Eni and Dompé farmaceutici Partner for Joint Research on Global Health Issues

Eni and Dompé farmaceutici Partner for Joint Research on Global Health Issues

(IN BRIEF) Eni CEO Claudio Descalzi and Dompé farmaceutici Executive Chairman Sergio Dompé have signed a Letter of Intent to initiate joint research and development efforts focused on public health and community well-being in regions where Eni operates, along with other pertinent global health concerns. Building on their previous participation in the European Exscalate4Cov project to address COVID-19 challenges, the two companies will leverage their molecular modeling expertise and high-performance computing capabilities for collaborative research. Eni will provide Dompé researchers access to its labs, specialized staff support, and use of its HPC5 supercomputer. The primary objective is to expedite the discovery of new medications and vaccines capable of responding swiftly and effectively to future healthcare crises. The agreement also encompasses the study of health security within emerging energy supply chains and ongoing surveillance of high-incidence infections in Eni-operated areas. This partnership aligns with Eni’s commitment to the well-being of its personnel and supports the principles of precaution, prevention, and well-being promotion outlined in the United Nations 2030 Agenda’s Sustainable Development Goals.

(PRESS RELEASE) MILAN, 10-Oct-2023 — /EuropaWire/ — Eni CEO Claudio Descalzi and Dompé farmaceutici Executive Chairman Sergio Dompé signed a Letter of Intent to launch joint research and development activities focusing on the health of people and communities in the areas where Eni operates, as well as other relevant global health issues.

Eni and Dompé farmaceutici decided to engage in joint research activities once again by pooling together their molecular modeling expertise and high-performance computing capabilities. This follows the two companies’ participation in the European Exscalate4Cov project, aimed at identifying solutions to the issues emerged during the COVID-19 pandemic.

In line with the Letter of Intent, Eni will guarantee Dompé researchers access to its laboratories, support from the company’s specialized staff, and use of its HPC5 supercomputer. The goal is accelerating the identification of new medicines and vaccines capable to respond more quickly and effectively to future healthcare emergencies. The Letter of Intent also encompasses the study of health security in relation to new energy supply chains, as well as periodic monitoring of high-incidence infections in area where Eni is present.

Today’s signing represents a further step for Eni to ensure the management of the health and well-being of its people, based on the principles of precaution, prevention, and promotion of well-being set out in the Sustainable Development Goals of the United Nations 2030 Agenda.

Media Contacts:

Press Office
Tel: +39.0252031875
Tel: +39.0659822030
ufficio.stampa@eni.com

SOURCE: Eni S.p.A.